Exhibiting at Middle East Poultry Expo 2025

Boehringer Ingelheim International GmbH, headquartered in Ingelheim am Rhein, Germany, is one of the world’s largest and most innovative pharmaceutical companies. Established in 1885, this family-owned enterprise has evolved into a global powerhouse in human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a legacy spanning over 135 years, Boehringer Ingelheim remains committed to driving medical innovation to improve lives worldwide.

Core Business and Offerings

Boehringer Ingelheim’s business is structured around three primary segments:

• Human Pharmaceuticals: Focused on respiratory diseases, cardiometabolic conditions, oncology, and diseases of the central nervous system.
• Animal Health: One of the top global providers of vaccines, antiparasitics, and therapeutics for companion and livestock animals.
• Biopharmaceuticals Contract Manufacturing (BioXcellence): Offers development and manufacturing services for third parties.

Key Products

• Human Pharmaceuticals:
  • Jardiance (empagliflozin) – Type 2 diabetes and heart failure
  • Ofev (nintedanib) – Idiopathic pulmonary fibrosis and interstitial lung diseases
  • Pradaxa (dabigatran etexilate) – Anticoagulant
  • Spiriva (tiotropium bromide) – COPD treatment
• Animal Health:
  • NexGard (afoxolaner) – Flea and tick treatment
  • Metacam (meloxicam) – Anti-inflammatory for animals
  • Vetmedin (pimobendan) – Canine heart disease
  • CircoFLEX – Vaccine against porcine circovirus

Specialization and USP

Boehringer Ingelheim’s unique value lies in its sustained investment in R&D and its long-term vision as a family-owned company. Key differentiators include:

• Independent R&D: In 2023, the company invested €5.8 billion into R&D, which is 21.1% of total net sales.
• Global Reach: Products and services available in more than 130 countries.
• Sustainability & Ethics: Strong focus on environmental sustainability and animal welfare.

Their animal health division is the second-largest globally, following their acquisition of Merial in 2017.

Financial Insights

Boehringer Ingelheim reported strong financial performance in 2023:

• Total Net Sales: €24.1 billion
• Human Pharmaceuticals Sales: €15.4 billion
• Animal Health Sales: €4.5 billion
• Net Income: €3.3 billion
• R&D Expenditure: €5.8 billion (24% of net sales)

These figures reflect the company’s robust growth strategy and reinvestment into innovation and development.

Shipment and Trade Records

Boehringer Ingelheim operates more than 180 affiliated companies worldwide and maintains production sites across Europe, the Americas, and Asia. Its products are routinely shipped globally through highly regulated and efficient supply chains, ensuring compliance with Good Manufacturing Practice (GMP) and international safety standards.

Target Market

• Healthcare providers and hospitals
• Veterinary clinics and livestock producers
• Biotech companies utilizing contract manufacturing
• Retail pharmaceutical and medical distributors

The company’s multichannel approach ensures global accessibility and tailored solutions for both human and animal health needs.

Capabilities and Infrastructure

• 52,000+ employees worldwide
• 13 global R&D centers
• State-of-the-art biopharma manufacturing under the BioXcellence brand
• Advanced logistics and regulatory frameworks

Their capabilities also include digital innovation initiatives, such as AI-driven drug discovery and digital therapeutics.

Certifications and Compliance

Boehringer Ingelheim adheres to global regulatory and quality standards:

• GMP (Good Manufacturing Practice)
• GLP (Good Laboratory Practice)
• ISO 9001, ISO 14001
• EMA and FDA compliance

Their quality assurance is integral to their position as a trusted pharmaceutical and animal health partner.

Customer Testimonials

While individual testimonials are proprietary, Boehringer’s reputation is reinforced by:

• Regular endorsements in peer-reviewed journals
• High ratings from healthcare providers and veterinarians
• Strategic partnerships with leading universities and biotech firms

Their consistent inclusion in “Best Places to Work” lists underscores strong internal and external trust.

Major Achievements

• Top 20 Global Pharma Company by sales
• Pioneered SGLT2-inhibitor class with Jardiance
• Award-winning pipeline in oncology and immunology
• Leader in animal vaccine innovation post-Merial acquisition
• Recognized for ESG and sustainability leadership across pharmaceutical indices

Boehringer Ingelheim continues to shape the future of healthcare through innovation, sustainability, and a deep commitment to global well-being.